Clinical trial · Observational
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Use of Evidence-Based Supportive Care Clinical Practice Guidelines in Pediatric Oncology
NCT02847130CI-TRIAL-00068089completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research trial studies the use of clinical practice guidelines by pediatric oncology healthcare providers in order to identify, understand, and overcome barriers to them. The treatments for childhood cancers are intense and result in a high rate of symptoms which require support by healthcare providers. By reviewing patients' medical chart records, meeting in focus groups and in one-on-one interviews, healthcare providers may improve how clinical practice guidelines are used to support children undergoing cancer treatment.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
| B-Cell Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Childhood Burkitt Lymphoma | Childhood Burkitt Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Neoplasm | Childhood Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Hematopoietic and Lymphoid Cell Neoplasm | Hematopoietic and Lymphoid Cell Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Malignant Solid Neoplasm | Malignant Solid Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Recurrent Childhood Acute Lymphoblastic Leukemia | Childhood Acute Lymphoblastic Leukemia | CURATED_BROADER |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Informational Intervention | Other | — | UNRESOLVED |
| Interview | Other | — | UNRESOLVED |
| Medical Chart Review | Other | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational (chart review, focus group, interviews)
- description
- AIM 1 (CHART REVIEW): Patients are separated for each CPG evaluated (fever and neutropenia \[FN\], chemotherapy induced nausea and vomiting \[CINV\], fertility preservation \[FP\]) and are randomly selected for medical chart review. Patients with eligible episodes of FN, CINV or FP within the health records are selected and have the data from their records abstracted and reviewed by COG for adherence to COG endorsed CPGs. AIM 2 (FOCUS GROUPS): Health care providers who provide direct care to pediatric oncology patients are identified and separated to participate in three types of focus groups: physician-only, non-physician, and mixed. AIM 3 (INTERVIEWS): Health care providers undergo one-on-one interviews consisting of think aloud technique (TAL) of cognitive interviewing.
- interventionNames
- Other: Informational Intervention
- Other: Interview
- Other: Medical Chart Review
- Other: Questionnaire Administration
Primary outcomes (6)
- measure
- The proportion of clinical practice guidelines (CPG)-consistent care of fever and neutropenia (FN) episodes
- timeFrame
- Care delivered from January 1, 2014 through December 31, 2015 will be evaluated
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria:
* Site willingness to participate in all 3 aims
* AIM 1 - ELIGIBILITY CRITERIA FOR INCLUSION IN RETROSPECTIVE CENTRALIZED CHART REVIEW
* Received care as an inpatient or outpatient at a participating COG NCORP site during the time period between January 1, 2014 and December 31, 2015
* Ever enrolled on any COG trial (episode does not have to occur while on trial and the COG trial may be therapeutic or non-therapeutic)
* Has at least one episode eligible for FN, CINV or FP review
* CPG-Specific Eligibility
* FN
* Has any of the following diagnoses:
* Newly diagnosed acute lymphoblastic leukemia
* Relapsed acute lymphoblastic leukemia
* Any acute myeloid leukemia
* Burkitt's or mature B cell non-Hodgkin's lymphoma
* Any myeloablative autologous or allogeneic hematopoietic stem cell transplantation
* Developed FN at least once
* CINV
* Diagnosis of cancer
* Received moderately emetogenic chemotherapy as an inpatient
* \< 12 years of age at the start of a CINV episode and received highly emetogenic chemotherapy as an in-patient
* FP
* Newly diagnosed cancer
* \>= 15 years of age at cancer diagnosis
* Note: a single patient may contribute data for multiple episodes
* AIM 2 AND AIM 3 INCLUSION CRITERIA
* Healthcare professional currently employed at a participating COG NCORP institution
* Eligible healthcare providers include but are not limited to: physicians, nurses, nurse practitioners, pharmacists, social workers, dieticians, psychologists, and physical therapists/physiotherapists
* Provides direct care for children with cancer as part of current position at NCORP site
Exclusion Criteria:
* AIM 2 AND AIM 3 EXCLUSION CRITERIA
* Trainees are excluded
* Previous participation in this study either for Aim 2 or Aim 3
* Each health care provider can only be involved in one event (focus group or interview)References
Publications (1)
- DERIVEDSugalski AJ, Lo T, Beauchemin M, Grimes AC, Robinson PD, Walsh AM, Santesso N, Dang H, Fisher BT, Wrightson AR, Yu LC, Sung L, Dupuis LL. Facilitators and barriers to clinical practice guideline-consistent supportive care at pediatric oncology institutions: a Children's Oncology Group study. Implement Sci Commun. 2021 Sep 16;2(1):106. doi: 10.1186/s43058-021-00200-2. PMID 34530933